In this study we are using new biologic features, in addition to the standard risk factors, to help decide which subjects need treatment and what the best treatment is. (Subjects are people who agree to take part in this study.) Subjects will be put into 1 of 3 different treatment groups, labeled as Group A, B and C. The group that you are put in will determine the treatment that you get.
The Children Brain Tumor Tissue Consortium (CBTTC) is a collaborative multi-institutional cooperative research program dedicated to the study of childhood brain tumors. The ultimate goal of the CBTTC is to improve outcomes for children with brain tumors by supporting research on new prognostic biomarkers and therapies. In order to achieve this, the consortium links high quality tumor specimens with clinical and genomic data in a de-identified manner. This information is then available to be requested by investigators worldwide. The results of the research is then filtered back into the project, sharing results and increasing collaboration to ultimately achieve better outcomes.
This study involves taking a study drug called CUDC-907. CUDC-907 is an oral drug that blocks certain
proteins in tumor cells; these proteins may be important in the growth of some
cancers. The overall goals of this study are to evaluate the side effects and
benefits of CUDC-907 in patients with relapsed or treatment refractory solid
tumor, brain tumor, or lymphoma, and to determine the best dose of CUDC-907 for
children and adolescents. This study
will also look at the levels of CUDC-907 in the blood over time after a dose.